INTEGRA LIFESCIENCES HOLDINGS CORP

For the period ended Jun 30, 2025. Filed Jul 31, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Jul 31, 2025

IART$14.53+1.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 1. Financial Statements

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE INCOME

(Dollars in thousands, except per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2025	2024	2025	2024
Total revenue, net	$415,605	$418,175	$798,258	$787,047
Costs and expenses:
Cost of goods sold	206,273	192,258	394,494	354,296
Research and development	26,997	29,767	51,725	56,732
Selling, general and administrative	179,890	195,472	361,387	361,270
Intangible asset amortization	3,754	3,707	7,458	13,814
Goodwill impairment charge	511,365	—	511,365	—
Total costs and expenses	928,279	421,204	1,326,429	786,112
Operating (loss) income	(512,674)	(3,029)	(528,171)	935
Interest income	4,710	5,058	9,130	10,098
Interest expense	(21,042)	(18,651)	(39,857)	(32,275)
Other (expense) income, net	(1,946)	1,437	(2,090)	827
Loss before income taxes	(530,952)	(15,185)	(560,988)	(20,415)
Benefit for income taxes	(46,879)	(2,783)	(51,622)	(4,732)
Net loss	$(484,073)	$(12,402)	$(509,366)	$(15,683)
Net loss per share
Basic and diluted	$(6.31)	$(0.16)	$(6.65)	$(0.20)
Weighted average common shares outstanding (See Note 13):
Basic and diluted	76,695	77,409	76,579	77,572
Comprehensive loss (See Note 14)	(490,874)	(20,482)	(512,702)	$(19,303)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.